Advanced early diagnosis tools and disease-modifying therapies are innovations in neurotechnology helping reshape care for neurodegenerative disorders . Some take the form of blood-based markers and protein quantification, while others are immunotherapies for active targeting.
Through these innovations, people with neurological conditions like Alzheimer’s disease (AD) and Parkinson’s disease can benefit from earlier and more precise diagnoses and treatment. They’re welcome additions to neurotechnology, given that such conditions affect one in two people in the U.S., per the American Academy of Neurology.
What Are the Most Common Neurodegenerative Diseases? AD and Parkinson’s disease are the most common neurodegenerative and progressive brain diseases in the United States. They’re more common among older adults but impact different parts of the brain.
AD primarily affects the areas of the brain responsible for cognitive function and memory. Conversely, Parkinson’s primarily impacts movement control centers.
An article published (and recently reviewed) by the National Institute of Environmental Health Sciences noted that AD affects as many as 6.2 million people in the United States. ...